Citations

Clear

4799 citation(s) found for "Yu, Jennifer".

GADD45A is a mediator of mitochondrial loss, atrophy, and weakness in skeletal muscle
Marcotte, George R. , Miller, Matthew J. , Ryan, Zachary C. , Strub, Matthew D. , Vanderboom, Patrick M. , Heppelmann, Carrie J. , Chau, Sarah, Ruff, Zachary D. Von, Kilroe, Sean P. , McKeen, Andrew T., Dierdorff, Jason M., Stern, Jennifer I. , Nath, Karl A. , Ebert, Scott M. , Adams, Christopher M. , Ebert, Scott M. , Adams, Christopher M , Kunz, Hawley , Chau, Sarah, Grueter, Chad Eric , Lira, Vitor Agnew , Judge, Andrew R. , Rasmussen, Blake B. , Nair, K. Sreekumaran , Lanza, Ian R.

Mayo Clinic

JCI Insight | October 10, 2023 | Volume: 8 | Issue: 22 | Pages: No page available

10.1172/jci.insight.171772 | PMID 37815864 Get It

Aging and many illnesses and injuries impair skeletal muscle mass and function, but the molecular mechanisms are not well understood. To better understand the mechanisms, we generated and studied transgenic mice with skeletal muscle–specific expression of growth arrest and DNA damage inducible α (GADD45A), a signaling protein whose expression in skeletal muscle rises during aging and a wide range of illnesses and injuries. We found that GADD45A induced several cellular changes that are characteristic of skeletal muscle atrophy, including a reduction in skeletal muscle mitochondria and oxidative capacity, selective atrophy of glycolytic muscle fibers, and paradoxical expression of oxidative myosin heavy chains despite mitochondrial loss. These cellular changes were at least partly mediated by MAP kinase kinase kinase 4, a protein kinase that is directly activated by GADD45A. By inducing these changes, GADD45A decreased the mass of muscles that are enriched in glycolytic fibers, and it impaired strength, specific force, and endurance exercise capacity. Furthermore, as predicted by data from mouse models, we found that GADD45A expression in skeletal muscle was associated with muscle weakness in humans. Collectively, these findings identify GADD45A as a mediator of mitochondrial loss, atrophy, and weakness in mouse skeletal muscle and a potential target for muscle weakness in humans.
Fat-Free Mass Index in a Large Sample of National Collegiate Athletic Association Men and Women Athletes From a Variety of Sports
Magee, Meghan K., Fields, Jennifer B. , Jones, Margaret T. , Jones, Margaret T , Jagim, Andrew R.

Mayo Clinic

Journal of Strength & Conditioning Research | October 10, 2023 | Volume: 38 | Issue: 2 | Pages: 311-317

10.1519/jsc.0000000000004621 | PMID 37815277 Get It

Abstract Magee, MK, Fields, JB, Jagim, AR, and Jones, MT. Fat-free mass index in a large sample of National Collegiate Athletic Association men and women athletes from a variety of sports. J Strength Cond Res 38(2): 311–317, 2024—Fat-free mass index (FFMI) can be used to categorize fat-free mass (FFM) relative to height. Normative values have been established in a variety of sports, as has suggested lower and upper thresholds of FFMI. However, FFMI has not been reported in a large sample of athletes, representing both sexes and multiple sport types. The purpose of this study was to evaluate differences in FFMI and establish normative values across a large sample of collegiate sports. A total of 1,961 athletes (men: n = 596, 10 sports; women: n = 1,365, 8 sports) participated. Height and mass were measured using a stadiometer and calibrated digital scale, respectively. Fat-free mass was assessed with air displacement plethysmography and used to calculate FFMI. Kruskal-Wallis test and one-way analysis of variance evaluated differences in FFMI in women's and men's sports, respectively. When collapsed across sport type and stratified by sex, men had a higher FFMI (21.5 ± 1.9 kg·m −2 vs. 17.9 ± 1.8 kg·m −2 ; p < 0.001). Differences occurred in FFMI across sport. In women, basketball athletes had the highest FFMI (18.9 kg·m −2 ) and highest 99th percentile for FFMI, whereas rowers had the lowest (16.9 kg·m −2 ). In men, throwers had the highest FFMI (25.7 kg·m −2 ) and highest 99th percentile, whereas volleyball athletes had the lowest (19.9 kg·m −2 ). Differences in FFMI may be attributable to dietary habits and physiological demands of respective sports. These results can provide information relative to differences in FFMI values across sports. In addition, sport-specific normative values can be used as benchmarks and targets for training, nutrition, and goal setting.
Biomarkers of cellular senescence and risk of death in humans
Weston, Susan A., Atkinson, Elizabeth J. , Gree, Michaela E. Mc, White, Thomas A. , Heeren, Amanda A., Rocca, Walter A. , Palmer, Allyson K. , Cummings, Steven R. , Fielding, Roger A. , St Sauver, Jennifer L , Mc Gree, Michaela E, Palmer, Allyson K , Bielinski, Suzette J. , LeBrasseur, Nathan K , Sauver, Jennifer L. St. , Mielke, Michelle M. , Olson, Janet E. , LeBrasseur, Nathan K.

Mayo Clinic

Aging Cell | October 8, 2023 | Volume: 22 | Issue: 12 | Pages: No page available

10.1111/acel.14006 | PMID 37803875 Get It

AbstractA robust and heterogenous secretory phenotype is a core feature of most senescent cells. In addition to mediators of age‐related pathology, components of the senescence associated secretory phenotype (SASP) have been studied as biomarkers of senescent cell burden and, in turn, biological age. Therefore, we hypothesized that circulating concentrations of candidate senescence biomarkers, including chemokines, cytokines, matrix remodeling proteins, and growth factors, could predict mortality in older adults. We assessed associations between plasma levels of 28 SASP proteins and risk of mortality over a median follow‐up of 6.3 years in 1923 patients 65 years of age or older with zero or one chronic condition at baseline. Overall, the five senescence biomarkers most strongly associated with an increased risk of death were GDF15, RAGE, VEGFA, PARC, and MMP2, after adjusting for age, sex, race, and the presence of one chronic condition. The combination of biomarkers and clinical and demographic covariates exhibited a significantly higher c‐statistic for risk of death (0.79, 95% confidence interval (CI): 0.76–0.82) than the covariates alone (0.70, CI: 0.67–0.74) (p < 0.001). Collectively, these findings lend further support to biomarkers of cellular senescence as informative predictors of clinically important health outcomes in older adults, including death.
Association Between Whole Blood–Derived Mitochondrial DNA Copy Number, Low‐Density Lipoprotein Cholesterol, and Cardiovascular Disease Risk
Liu, Xue , Sun, Xianbang, Jiang, Wenqing , Lai, M M , Wiggins, Kerri L. , Raffield, Laura M. , Bielak, Lawrence F. , Zhao, Wei , Pitsillides, Achilleas , Haessler, Jeffrey, Blackwell, Thomas W. , Yao, Jie , Qian, Yong , Thyagarajan, Bharat , Peyser, Patricia A. , Heckbert, Susan R. , Seshadri, Sudha , Boerwinkle, Eric , Grove, Megan L. , Larson, Nicholas B. , Smith, Jennifer A. , Fitzpatrick, Annette L., Fornage, Myriam , Ding, Jun , Carson, April P. , Reiner, Alex P. , Hou, Lifang , Wilson, James G. , Rotter, Jerome I. , Bis, Joshua C. , Arking, Dan E. , Zhao, Wei , Wiggins, Kerri L , Raffield, Laura M , Bielak, Lawrence F , Zhao, Wei , Pitsillides, Achilleas , Zheng, Yinan , Yao, Jie , Guo, Xiuqing , Thyagarajan, Bharat , Pankratz, Nathan , Rich, Stephen S , Taylor, Kent D , Peyser, Patricia A , Heckbert, Susan R , Boerwinkle, Eric , Larson, Nicholas B , Smith, Jennifer A , Vasan, Ramachandran S , Fornage, Myriam , Carson, April P , Dupuis, Josée , Reiner, Alexander P , Hou, Lifang , Psaty, Bruce M , Levy, Daniel , Rotter, Jerome I , Bis, Joshua C , Satizabal, Claudia L , Arking, Dan E , Liu, Chunyu , Seshadri, Sudha , Zhang, Yuankai , Zheng, Yinan , Guo, Xiuqing , Pankratz, Nathan , Rich, Stephen S. , Taylor, Kent D. , Vasan, Ramachandran S. , Abecasis, Gonçalo R. , Kooperberg, Charles , Psaty, Bruce M. , Levy, Daniel , Satizábal, Claudia L.

Mayo Clinic

Journal of the American Heart Association | October 7, 2023 | Volume: 12 | Issue: 20 | Pages: No page available

10.1161/jaha.122.029090 | PMID 37804200 Get It

Background The relationship between mitochondrial DNA copy number (mtDNA CN) and cardiovascular disease remains elusive. Methods and Results We performed cross‐sectional and prospective association analyses of blood‐derived mtDNA CN and cardiovascular disease outcomes in 27 316 participants in 8 cohorts of multiple racial and ethnic groups with whole‐genome sequencing. We also performed Mendelian randomization to explore causal relationships of mtDNA CN with coronary heart disease (CHD) and cardiometabolic risk factors (obesity, diabetes, hypertension, and hyperlipidemia). P <0.01 was used for significance. We validated most of the previously reported associations between mtDNA CN and cardiovascular disease outcomes. For example, 1‐SD unit lower level of mtDNA CN was associated with 1.08 (95% CI, 1.04–1.12; P <0.001) times the hazard for developing incident CHD, adjusting for covariates. Mendelian randomization analyses showed no causal effect from a lower level of mtDNA CN to a higher CHD risk (β=0.091; P =0.11) or in the reverse direction (β=−0.012; P =0.076). Additional bidirectional Mendelian randomization analyses revealed that low‐density lipoprotein cholesterol had a causal effect on mtDNA CN (β=−0.084; P <0.001), but the reverse direction was not significant ( P =0.059). No causal associations were observed between mtDNA CN and obesity, diabetes, and hypertension, in either direction. Multivariable Mendelian randomization analyses showed no causal effect of CHD on mtDNA CN, controlling for low‐density lipoprotein cholesterol level ( P =0.52), whereas there was a strong direct causal effect of higher low‐density lipoprotein cholesterol on lower mtDNA CN, adjusting for CHD status (β=−0.092; P <0.001). Conclusions Our findings indicate that high low‐density lipoprotein cholesterol may underlie the complex relationships between mtDNA CN and vascular atherosclerosis.
Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study
Palmer, Mathias Earl, Jin, Zhaohui , Palmer, Mathias E, Gile, Jennifer J, Jin, Zhaohui , Zemla, Tyler J, Gile, Jennifer , Storandt, Michael H. , Zemla, Tyler , Tran, Nguyen H. , Mahipal, Amit

Mayo Clinic

Cancers | October 6, 2023 | Volume: 15 | Issue: 19 | Pages: 4867

10.3390/cancers15194867 | PMID 37835561 Get It

Background: Lenvatinib, a multikinase inhibitor, is an FDA-approved treatment for advanced hepatocellular carcinoma (HCC) in the first-line setting. Recent trial data have established atezolizumab plus bevacizumab as well as tremelimumab plus durvalumab as preferred first-line treatment options for advanced HCC. The role of lenvatinib following progression on immunotherapy in patients with advanced HCC remains unclear. Methods: We conducted a multicentric, retrospective analysis of patients with advanced HCC diagnosed between 2010 and 2021 at the Mayo Clinic in Minnesota, Arizona, and Florida who received immunotherapy followed by lenvatinib. Median overall survival and progression-free survival analyses were performed using the Kaplan–Meier method, and responses were determined using RECIST 1.1. Adverse events were determined using CTCAE v 4.0. Results: We identified 53 patients with advanced HCC who received lenvatinib following progression on immunotherapy. Forty five (85%) patients had a Child Pugh class A at diagnosis, while 30 (58%) patients were still Child Pugh A at time of lenvatinib initiation. Lenvatinib was administered as a second-line treatment in 85% of the patients. The median PFS was 3.7 months (95% CI: 3.2–6.6), and the median OS from the time of lenvatinib initiation was 12.8 months (95% CI: 6.7–19.5). In patients with Child Pugh class A, the median OS and PFS was 14 and 5.2 months, respectively. Race, gender, and Child Pugh class was associated with OS on multivariate analysis. Discussion: Our study, using real-world data, suggests that patients benefit from treatment with lenvatinib following progression on immunotherapy in advanced HCC. The optimal sequencing of therapy for patients with advanced HCC following progression on immunotherapy remains unknown, and these results need to be validated in a clinical trial.
OR29-06 Flare-Ups In Patients With Fibrodysplasia Ossificans Progressiva Reduced By Garetosmab Treatment: LUMINA-1 Data
McGinniss, Jennifer, Forleo‐Neto, Eduardo , Mellis, Scott , Sanchez, Robert J., Rocco, Maja Di , Roux, Christian , Mukaddam, Mona Al , Srinivasan, Dushyanth , Rankin, A. J., Trotter, Dinko González , Eekhoff, Marelise, Pignolo, Robert J. , Dahir, Kathryn , Keen, Richard , Orcel, Philippe , Tabarkiewicz, Jacek , Bachiller‐Corral, Javier , Cheung, Angela M. , Mohammadi, Kusha , Economides, Aris N. , Kaplan, Frederick S.

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.571 Get It

Abstract Disclosure: K.M. Dahir: Consulting Fee; Self; Alexion Pharmaceuticals, Inc., Ultragenyx, Inozyme, AM Pharma. Grant Recipient; Self; Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Inc., AstraZeneca, Ultragenyx. J. McGinniss: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. E. Forleo-Neto: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. S. Mellis: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. R.J. Sanchez: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. M. Di Rocco: Research Investigator; Self; Regeneron Pharmaceuticals, Ipsen. R. Keen: Advisory Board Member; Self; International Clinical Council on FOP and IFOPA Registry. Research Investigator; Self; Ipsen, Regeneron Pharmaceuticals, Clementia. P. Orcel: Research Investigator; Self; Regeneron Pharmaceuticals. C. Roux: Consulting Fee; Self; Alexion Pharmaceuticals, Inc., Amgen Inc. Grant Recipient; Self; Regeneron Pharmaceuticals, Kyowa, Kirin Brewery, Alexion Pharmaceuticals, Inc. J. Tabarkiewicz: Speaker; Self; Merck, Novartis Pharmaceuticals. Other; Self; SoftSystem. J. Bachiller-Corral: Research Investigator; Self; Regeneron Pharmaceuticals. A.M. Cheung: Consulting Fee; Self; Ipsen. Grant Recipient; Self; Ipsen, Incyte, Regeneron Pharmaceuticals. M. Al Mukaddam: Grant Recipient; Self; Ipsen, Clementia, Incyte, Regeneron Pharmaceuticals. K. Mohammadi: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. D. Srinivasan: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. A. Rankin: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. A.N. Economides: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. D. Gonzalez Trotter: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. F.S. Kaplan: Research Investigator; Self; Regeneron Pharmaceuticals, Clementia, Ipsen. M.W. Eekhoff: Grant Recipient; Self; Regeneron Pharmaceuticals, Ipsen, AstraZeneca, IMI, IFOPA. R.J. Pignolo: Grant Recipient; Self; Regeneron Pharmaceuticals, Clementia, Ipsen, Incyte. Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare autosomal dominant disorder driven by missense mutations in ACVR1. This results in inappropriate activation by activin-A. FOP is characterized by progressive heterotopic ossification and painful soft tissue inflammatory events known as flare-ups. Garetosmab, an investigational, fully human monoclonal antibody against activin-A, prevents formation of new heterotopic ossification lesions in FOP. Here we describe the impact of garetosmab on flare-up events in the LUMINA-1 study (NCT03188666). Methods: This was a post hoc analysis of phase 2 LUMINA-1, a randomized double-blind placebo-controlled study that evaluated the safety and efficacy of garetosmab 10 mg/kg/every 4 weeks intravenous vs placebo in adult patients with FOP over 28 weeks (Period 1), followed by a 28-week open-label treatment period (Period 2) and subsequent open-label extension (Period 3). Patient-reported flare-ups were collected via a patient diary and severity of symptoms was reported as mild, moderate, or severe. Clinician-reported flare-ups were collected as adverse events. Results: In Period 1, there was a significant reduction in the proportion of patients reporting one or more flare-ups (35% vs 71%, p=0.032) and clinician-reported flare-ups (10% vs 42%, p=0.039) with garetosmab vs placebo, respectively. The overall number of patient-reported flare-ups (13 vs 34) and mean days experiencing new flare-ups (42.6 days vs 65.4 days) were also reduced with garetosmab vs placebo, respectively. Most flare-ups occurred in the back in garetosmab-treated patients, and most flare-ups occurred in the lower extremities and back for those on placebo. Pain was the most frequent symptom among both cohorts. Flare-up associated joint stiffness and severity of flare-up associated symptoms were nominally reduced at both patient and flare-up level of assessment in those treated with garetosmab. No patients reported severe swelling or severe decrease in movement. One patient reported severe pain and joint stiffness in the garetosmab cohort. In Period 2, there were significant reductions in the proportion of patients experiencing flare-ups (68% vs 14%, p=0.0002) and number of patient-reported flares (31 vs 11) among those who crossed over from placebo in Period 1 to garetosmab. Patients who continued on garetosmab through Period 2 maintained a sustained reduction in number of flare-ups (12 vs 6) and proportion of patients experiencing flare-ups (33.3% vs 22.2%). Reductions were maintained through the open-label extension. Conclusions: Patients treated with garetosmab experienced significant and sustained reductions in the frequency, duration, and severity of flare-ups. The ability of garetosmab to reduce flare-up events may provide a clinically meaningful benefit for patients with FOP. Presentation: Sunday, June 18, 2023
Consensus statement: An evidence‐based review of exercise, rehabilitation, rest, and return to activity protocols for the treatment of concussion and mild traumatic brain injury
Luigi, Arthur Jason De , Bell, Kathleen , Bramhall, Joe P., Choe, Meeryo , Dec, Katherine L., Halstead, Mark, Herring, Stanley A., Matuszak, Jason, Raksin, P B , Swanson, Jennifer, Millett, Carolyn, De Luigi, Arthur J , Bell, Kathleen , Finnoff, Jonathan T. , Halstead, Mark, Swanson, Jennifer, Millett, Carolyn

Mayo Clinic

PM&R | October 5, 2023 | Volume: 15 | Issue: 12 | Pages: 1605-1642

10.1002/pmrj.13070 | PMID 37794736 Get It

Abstract Background Early diagnosis and appropriate management of concussion/mild traumatic brain injury (mTBI) is critical for preventing poor outcomes and minimizing health care burden. Current clinical guidelines for concussion management focus mostly on diagnosis and return to cognitive and physical activity but provide limited guidance on the use of specific therapeutic interventions. Objective To systematically review the available evidence on therapeutic interventions for concussion/mTBI and develop an evidence‐based consensus statement on the use of these interventions in clinical practice. Literature Survey A systematic literature search was performed first in 2018 and 2019, and again in 2022, to identify relevant original research on these interventions. A total of 6303 articles were retrieved through the systematic literature search and screened for inclusion. Eighty articles met inclusion criteria and were included in this review and consensus process. Methodology A multispecialty panel was convened to explore management of concussion/mTBI. Interventions evaluated included rest, exercise, rehabilitation, and return to activity (RTA) protocols. Studies were assessed for relevance and methodologic quality and were voted upon to develop an evidence‐based consensus statement on the therapeutic appropriateness of these interventions for concussion/mTBI. A meta‐analysis was not performed. Synthesis There was sufficient evidence to recommend exercise as an appropriate therapy for adolescents with acute concussion/mTBI. In other age groups and for other therapeutic modalities, although some studies demonstrated benefits for some of the interventions, mixed results and study limitations prevented the panel from drawing firm conclusions on the efficacy of those interventions. The panel found evidence of detrimental effects from strict rest and high‐intensity physical activity. Conclusions The panel recommended exercise as an appropriate therapy for acute concussion in adolescents. The evidence on other therapeutic interventions for concussion/mTBI remains limited to small randomized controlled trials and observational studies of moderate to low quality. The panel found no strong evidence to support or recommend against the other evaluated interventions but found most interventions to be safe when used judiciously and in consideration of individual patient needs. High‐quality randomized studies with sufficient power are needed to evaluate the effects of rest, rehabilitation, and RTA protocols for the management of concussion/mTBI.
Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior
Gupta, Sounak , Sholl, Lynette M. , Osunkoya, Adeboye O. , Gordetsky, Jennifer , Cornejo, Kristine M. , Dvindenko, Eugénia, Hirsch, Michelle S. , Rowsey, Ross, Jiménez, Rafael E. , Cheville, John C. , Colecchia, Maurizio , Ricci, Costantino , Ulbright, Thomas M. , Snuderl, Matija , Rowsey, Ross A, Acosta, Andrés M , Gordetsky, Jennifer B , Yang, Yiying , Michalova, Kvetoslava , Maclean, Fiona M. , Snuderl, Matija , Anderson, William J. , Sadow, Peter M. , Berney, Daniel M. , Acosta, Andrés

Mayo Clinic

The Journal of Pathology | October 4, 2023 | Volume: 262 | Issue: 1 | Pages: 50-60

10.1002/path.6210 | PMID 37792634 Get It

Abstract Spermatocytic tumor (ST) is a rare type of germ cell tumor that occurs exclusively in the postpubertal testis and typically affects elderly men. Most STs are benign, but rare cases exhibit aggressive clinical behavior, often in association with transition to sarcomatoid histology. Limited molecular analyses have been performed on STs; therefore, their genomic and epigenomic features remain incompletely described. Twenty‐seven samples from 25 individual patients were analyzed with a combination of DNA sequencing panels, genomic methylation profiling, SNP array, isochromosome (12p) [i(12p)] FISH, and immunohistochemistry. The series included five metastasizing tumors (three with sarcomatoid transformation, one anaplastic, and one conventional) and 20 non‐metastasizing tumors (14 anaplastic and six conventional). Anaplastic tumors comprised a monomorphic population of intermediate‐sized neoplastic cells, as previously described. Multiomic analyses demonstrated that there were two genomic subgroups of STs: one with diploid genomes and hotspot RAS / RAF variants and the other with global ploidy shift and absence of recurrent mutations. Relative gain of chromosome 9 was a consistent finding in both subgroups. A comparison of metastasizing and non‐metastasizing cases demonstrated that aggressive behavior was associated with the acquisition of pathogenic TP53 mutations and/or relative gains of 12p/i(12p). In cases with sarcomatoid transformation, TP53 mutations seem to underlie the transition to sarcomatoid histology. Genomic methylation analysis demonstrated that aggressive cases with gains of 12p cluster closer to pure seminomas than to STs without gains of 12p. In conclusion, STs include two genomic subgroups, characterized by global ploidy shifts without recurrent mutations and diploid genomes with RAS / RAF hotspot mutations, respectively. Biologic progression was associated with relative gains of 12p and TP53 mutations. The findings in STs with relative gains of 12p suggest that they may exhibit biologic characteristics akin to those seen in germ cell neoplasia in situ ‐related germ cell tumors rather than non‐germ cell neoplasia in situ ‐derived STs. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.